WebNov 8, 2024 · Phase 3 trials will be needed before the company who developed baxdrostat, CinCor Pharma, can submit data for approval by the U.S. Food and Drug Administration. Currently, patients with resistant ... WebNov 7, 2024 · Baxdrostat is the first contender in a new drug class that inhibits the enzyme that makes aldosterone rather than blocking the mineralocorticoid receptor, which is how spironolactone works. “The challenge with developing this class of drug is that the enzyme that makes aldosterone and the enzyme that makes cortisol are 93% identical,” said Brown.
Baxdrostat Drug Information, Uses, Side Effects, Chemistry ...
WebBaxdrostat for Treatment-Resistant Hypertension In patients with treatment-resistant hypertension and blood pressure of 130/80 mm Hg or higher, the aldosterone synthase … WebFeb 2, 2024 · Baxdrostat-related increases in the potassium level to 6.0 mmol per liter or greater occurred in 2 patients, but these increases did not recur after withdrawal and … jon wershow
AstraZeneca to Expand Cardiorenal Portfolio in CinCor Buyout
WebAug 22, 2024 · Baxdrostat (CIN-107) is a highly selective, potent, once daily, oral inhibitor of aldosterone synthase. The presentation will include clinical data from the randomized, Phase 1, placebo... WebJan 11, 2024 · Baxdrostat, an aldosterone synthase inhibitor, is a potential next-generation therapy for lowering blood pressure in patients with treatment-resistant hypertension. AstraZeneca seeks to combine baxdrostat with its blockbuster diabetes, heart failure and kidney disease drug Farxiga (dapagliflozin), which saw global sales of approximately $3 ... WebNov 28, 2024 · CinCor’s baxdrostat works differently than ACE inhibitors and ARBs. The small molecule is designed to block an enzyme that is key to aldosterone synthesis in the adrenal gland. This approach is... jon wertheim australian open